Agilent Technologies Inc. Stock
Agilent Technologies is a leading global manufacturer of measuring instruments, software, services, and solutions for chemical analysis, life sciences, diagnostics, and electronic testing. The company provides a broad range of products from laboratory equipment to genetic testing tools and clinical diagnostics. Agilent's instruments are widely used in research laboratories, pharmaceutical companies, and government agencies, making it a significant player in the life sciences industry. The company operates in more than 100 countries and has a history of innovation, having developed some of the world's first portable gas chromatographs and UV-Vis spectrophotometers. Agilent's stock is traded on the New York Stock Exchange under the symbol "A."
Pros and Cons of Agilent Technologies Inc. in the next few years
Pros
Cons
Performance of Agilent Technologies Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Agilent Technologies Inc. | -1.700% | -1.559% | 3.226% | 19.284% | 2.372% | 8.352% | -6.578% |
| Veeva Systems A | 1.200% | 7.840% | 13.812% | -29.073% | -7.702% | -4.820% | -36.988% |
| Boston Scientific | 1.250% | 4.084% | 8.487% | -55.957% | -50.221% | -14.080% | 5.384% |
| Waters Corp. | -1.700% | -0.728% | -0.365% | 29.277% | -0.183% | 29.841% | -0.848% |
sharewise BeanCounterBot AI-generated
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Agilent Technologies (A) – FY2025 Annual Report
Agilent appears to have returned to top-line growth in fiscal 2025, with revenue of roughly $6.95 billion representing a recovery of nearly 7% after a softer FY2024. Net income of $1.3 billion edged slightly higher, though the modest 1% profit growth relative to the stronger revenue rebound suggests margins came under some pressure during the year.
That margin dynamic stands out in the details. Gross margin appears to have slipped to around 52% from roughly 54% a year earlier, and operating margin similarly softened to about 21%. Because revenue grew while profitability compressed, the additional volume seems to have carried a higher relative cost, potentially reflecting mix shifts. The Agilent CrossLab segment—the recurring, services-oriented business—continues to grow steadily and now represents the largest contributor to segment operating income, while the more cyclical Life Sciences and Diagnostics segment recovered from its FY2024 trough without fully returning to prior peaks. Notably, research and development spending declined modestly to $455 million even as revenue rose, which could warrant observation given the company's innovation-driven positioning.
Comments
News
Why Agilent Technologies Stock Triumphed on Thursday
Agilent Technologies (NYSE: A) had a Thursday to remember, at least as far as its equity was concerned. The medical device and healthcare tech specialist posted its latest quarterly earnings report
Agilent Technologies Q2 Earnings Call Highlights
Key Points
- Interested in Agilent Technologies, Inc.? Here are five stocks we like better.
- Agilent raised its fiscal 2026 outlook after a strong second quarter, with revenue of $1.83 billion
The Often-Missed Corner of Healthcare That Wall Street Is Loving
The healthcare industry is notoriously volatile—company fortunes can be made or broken on the success of a single product or the results of a clinical trial, and it's not uncommon for stocks in